Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus
Background This study investigated the real-world efficacy and safety of insulin degludec/insulin aspart (IDegAsp) in Korean adults with type 2 diabetes mellitus (T2DM), whose insulin treatment was switched to IDegAsp. Methods This was a multicenter, retrospective, observational study comprising two...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Diabetes Association
2024-09-01
|
| Series: | Diabetes & Metabolism Journal |
| Subjects: | |
| Online Access: | http://www.e-dmj.org/upload/pdf/dmj-2023-0297.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850265221173608448 |
|---|---|
| author | Shinae Kang Yu-Bae Ahn Tae Keun Oh Won-Young Lee Sung Wan Chun Boram Bae Amine Dahaoui Jin Sook Jeong Sungeun Jung Hak Chul Jang |
| author_facet | Shinae Kang Yu-Bae Ahn Tae Keun Oh Won-Young Lee Sung Wan Chun Boram Bae Amine Dahaoui Jin Sook Jeong Sungeun Jung Hak Chul Jang |
| author_sort | Shinae Kang |
| collection | DOAJ |
| description | Background This study investigated the real-world efficacy and safety of insulin degludec/insulin aspart (IDegAsp) in Korean adults with type 2 diabetes mellitus (T2DM), whose insulin treatment was switched to IDegAsp. Methods This was a multicenter, retrospective, observational study comprising two 26-week treatment periods, before and after switching to IDegAsp, respectively. Korean adults with uncontrolled T2DM treated with basal or premix insulin (±oral antidiabetic drugs) were enrolled. The primary objective was to compare the degree of glycosylated hemoglobin (HbA1c) change in each 26-week observation period. The analyses included changes in HbA1c, fasting plasma glucose (FPG), body weight, proportion of participants achieving HbA1c <7.0%, hypoglycemic events, and total daily insulin dose (ClinicalTrials.gov, number NCT04656106). Results In total, 196 adults (mean age, 65.95 years; mean T2DM duration, 18.99 years) were analyzed. The change in both HbA1c and FPG were significantly different between the pre-switching and the post-switching period (0.28% vs. –0.51%, P<0.001; 5.21 mg/dL vs. –23.10 mg/dL, P=0.005), respectively. After switching, the rate of achieving HbA1c <7.0% was significantly improved (5.10% at baseline vs. 11.22% with IDegAsp, P=0.012). No significant differences (before vs. after switching) were observed in body weight change, and total daily insulin dose. The rates of overall and severe hypoglycemia were similar in the two periods. Conclusion In real-world clinical practice in Korea, the change of insulin regimen to IDegAsp was associated with an improvement in glycemic control without increase of hypoglycemia, supporting the use of IDegAsp for patients with T2DM uncontrolled with basal or premix insulin. |
| format | Article |
| id | doaj-art-6eb6797552ce4bcfb7a4a27b90c0bf05 |
| institution | OA Journals |
| issn | 2233-6079 2233-6087 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Korean Diabetes Association |
| record_format | Article |
| series | Diabetes & Metabolism Journal |
| spelling | doaj-art-6eb6797552ce4bcfb7a4a27b90c0bf052025-08-20T01:54:30ZengKorean Diabetes AssociationDiabetes & Metabolism Journal2233-60792233-60872024-09-0148592993610.4093/dmj.2023.02972827Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes MellitusShinae Kang0Yu-Bae Ahn1Tae Keun Oh2Won-Young Lee3Sung Wan Chun4Boram Bae5Amine Dahaoui6Jin Sook Jeong7Sungeun Jung8Hak Chul Jang9 Division of Endocrinology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea Novo Nordisk Pharma Korea Limited, Seoul, Korea Novo Nordisk Region Asia Pacific, Dubai, United Arab Emirates Novo Nordisk Pharma Korea Limited, Seoul, Korea Novo Nordisk Region Asia Pacific, Dubai, United Arab Emirates Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KoreaBackground This study investigated the real-world efficacy and safety of insulin degludec/insulin aspart (IDegAsp) in Korean adults with type 2 diabetes mellitus (T2DM), whose insulin treatment was switched to IDegAsp. Methods This was a multicenter, retrospective, observational study comprising two 26-week treatment periods, before and after switching to IDegAsp, respectively. Korean adults with uncontrolled T2DM treated with basal or premix insulin (±oral antidiabetic drugs) were enrolled. The primary objective was to compare the degree of glycosylated hemoglobin (HbA1c) change in each 26-week observation period. The analyses included changes in HbA1c, fasting plasma glucose (FPG), body weight, proportion of participants achieving HbA1c <7.0%, hypoglycemic events, and total daily insulin dose (ClinicalTrials.gov, number NCT04656106). Results In total, 196 adults (mean age, 65.95 years; mean T2DM duration, 18.99 years) were analyzed. The change in both HbA1c and FPG were significantly different between the pre-switching and the post-switching period (0.28% vs. –0.51%, P<0.001; 5.21 mg/dL vs. –23.10 mg/dL, P=0.005), respectively. After switching, the rate of achieving HbA1c <7.0% was significantly improved (5.10% at baseline vs. 11.22% with IDegAsp, P=0.012). No significant differences (before vs. after switching) were observed in body weight change, and total daily insulin dose. The rates of overall and severe hypoglycemia were similar in the two periods. Conclusion In real-world clinical practice in Korea, the change of insulin regimen to IDegAsp was associated with an improvement in glycemic control without increase of hypoglycemia, supporting the use of IDegAsp for patients with T2DM uncontrolled with basal or premix insulin.http://www.e-dmj.org/upload/pdf/dmj-2023-0297.pdfdatabases, factualdiabetes mellitus, type 2glycemic controlhypoglycemiainsulin degludec, insulin aspart drug combination |
| spellingShingle | Shinae Kang Yu-Bae Ahn Tae Keun Oh Won-Young Lee Sung Wan Chun Boram Bae Amine Dahaoui Jin Sook Jeong Sungeun Jung Hak Chul Jang Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus Diabetes & Metabolism Journal databases, factual diabetes mellitus, type 2 glycemic control hypoglycemia insulin degludec, insulin aspart drug combination |
| title | Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus |
| title_full | Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus |
| title_fullStr | Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus |
| title_full_unstemmed | Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus |
| title_short | Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus |
| title_sort | efficacy and safety of idegasp in a real world korean population with type 2 diabetes mellitus |
| topic | databases, factual diabetes mellitus, type 2 glycemic control hypoglycemia insulin degludec, insulin aspart drug combination |
| url | http://www.e-dmj.org/upload/pdf/dmj-2023-0297.pdf |
| work_keys_str_mv | AT shinaekang efficacyandsafetyofidegaspinarealworldkoreanpopulationwithtype2diabetesmellitus AT yubaeahn efficacyandsafetyofidegaspinarealworldkoreanpopulationwithtype2diabetesmellitus AT taekeunoh efficacyandsafetyofidegaspinarealworldkoreanpopulationwithtype2diabetesmellitus AT wonyounglee efficacyandsafetyofidegaspinarealworldkoreanpopulationwithtype2diabetesmellitus AT sungwanchun efficacyandsafetyofidegaspinarealworldkoreanpopulationwithtype2diabetesmellitus AT borambae efficacyandsafetyofidegaspinarealworldkoreanpopulationwithtype2diabetesmellitus AT aminedahaoui efficacyandsafetyofidegaspinarealworldkoreanpopulationwithtype2diabetesmellitus AT jinsookjeong efficacyandsafetyofidegaspinarealworldkoreanpopulationwithtype2diabetesmellitus AT sungeunjung efficacyandsafetyofidegaspinarealworldkoreanpopulationwithtype2diabetesmellitus AT hakchuljang efficacyandsafetyofidegaspinarealworldkoreanpopulationwithtype2diabetesmellitus |